Logo.jpg
CELSION CORPORATION ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING
31 mars 2021 08h00 HE | Celsion CORP
LAWRENCEVILLE, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...
Logo.jpg
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
23 févr. 2021 08h00 HE | Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years LAWRENCEVILLE, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a...
CocrystalPharmaInc.jpg
Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference
06 nov. 2020 08h00 HE | Cocrystal Pharma, Inc.
– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST – BOTHELL, WA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP),...
CocrystalPharmaInc.jpg
Cocrystal Pharma Provides Update on Influenza A Program
19 oct. 2020 08h05 HE | Cocrystal Pharma, Inc.
– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
02 oct. 2020 08h05 HE | Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP) The following is being released by Cocrystal Pharma, Inc. pursuant to an order of the United States District...
CocrystalPharmaInc.jpg
Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
08 sept. 2020 08h00 HE | Cocrystal Pharma, Inc.
– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14th at 3:30 PM EDT – BOTHELL, WA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP),...
CocrystalPharmaInc.jpg
Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million
26 août 2020 22h00 HE | Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces $10.0 Million Bought Deal Offering
26 août 2020 17h35 HE | Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
CocrystalPharmaInc.jpg
Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
06 août 2020 08h05 HE | Cocrystal Pharma, Inc.
– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviralagents progresses – ...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market
27 févr. 2020 07h00 HE | Cocrystal Pharma, Inc.
BOTHELL, WA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...